
Sigilon Therapeutics, Inc. (Nasdaq: SGTX), relating to its proposed sale to Eli Lilly and Co. Under the terms of the agreement, SGTX shareholders are expected to receive $14.92 in cash per share they own plus one contingent value right worth up to $111.64.